These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3632385)

  • 1. Treatment of myasthenia gravis with pyridostigmine.
    Grogan WA
    Arch Neurol; 1987 Oct; 44(10):995-6. PubMed ID: 3632385
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinsonism induced by pyridostigmine.
    Iwasaki Y; Wakata N; Kinoshita M
    Acta Neurol Scand; 1988 Sep; 78(3):236. PubMed ID: 3227809
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Stokes-Adams attacks in myasthenia gravis: a possible cholinergic side effect.
    Ferguson JH; Turel AP
    Arch Neurol; 1976 Apr; 33(4):308. PubMed ID: 1259650
    [No Abstract]   [Full Text] [Related]  

  • 4. Memory impairment in myasthenia gravis.
    Riker WF
    Neurology; 1989 Apr; 39(4):611-2. PubMed ID: 2927695
    [No Abstract]   [Full Text] [Related]  

  • 5. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
    Sieb JP; Köhler W
    Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocytoclastic Vasculitis Secondary to Pyridostigmine (Mestinon): Report of a Possible First Case.
    Singh G; Hodgson T; Clarke DE
    Perm J; 2017; 21():15-240. PubMed ID: 28080955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spuriously elevated serum chloride values caused by pyridostigmine bromide.
    Ruff RL
    Arch Neurol; 1981 May; 38(5):321. PubMed ID: 7224925
    [No Abstract]   [Full Text] [Related]  

  • 8. Spurious hyperchloremia and hyperbicarbonatemia in a patient receiving pyridostigmine bromide therapy for myasthenia gravis.
    Wacks I; Oster JR; Pérez GO; Kett DH
    Am J Kidney Dis; 1990 Jul; 16(1):76-9. PubMed ID: 2368710
    [No Abstract]   [Full Text] [Related]  

  • 9. Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
    Lorenzoni PJ; Kay CSK; Ducci RD; Fustes OJH; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2020 Mar; 78(3):179-181. PubMed ID: 32215460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint pain and hyperalgesia due to pyridostigmine bromide in a patient with myasthenia gravis.
    Rostedt A; Stålberg E
    Neurology; 2004 Mar; 62(5):835-6. PubMed ID: 15007152
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pro-arrhythmia effect of pyridostigmine. Apropos of a case].
    Leenhardt A; Thomas O; Haouala H; Benaïm R; Maison-Blanche P; Cauchemez B; Haguenau M; Coumel P; Slama R
    Arch Mal Coeur Vaiss; 1992 Dec; 85(12):1853-6. PubMed ID: 1306628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridostigmine-induced dystonic blepharospasm in a patient with ocular myasthenia gravis.
    Voon YC; Yahya WN; Hasan S; Ibrahim NM
    Mov Disord; 2010 Jul; 25(9):1299-300. PubMed ID: 20629121
    [No Abstract]   [Full Text] [Related]  

  • 13. Malabsorption of pyridostigmine in patients with myasthenia gravis.
    Cohan SL; Dretchen KL; Neal A
    Neurology; 1977 Mar; 27(3):299-301. PubMed ID: 557769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyridostigmine levels in myasthenia gravis.
    Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
    Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
    [No Abstract]   [Full Text] [Related]  

  • 15. Coexistence of Parkinson's disease and myasthenia gravis: a case report.
    Kao KP; Kwan SY; Lin KP; Chang YC
    Clin Neurol Neurosurg; 1993 Jun; 95(2):137-9. PubMed ID: 8344012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal clearance of pyridostigmine in patients with myasthenia gravis.
    Chan K; Calvey TN
    Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma pyridostigmine levels in myasthenia gravis.
    White MC; De Silva P; Havard CW
    Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
    Tripathi M; Kaushik S; Dubey P
    J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxic alopecia caused by pyridostigmine bromide.
    Field LM
    Arch Dermatol; 1980 Oct; 116(10):1103. PubMed ID: 7425657
    [No Abstract]   [Full Text] [Related]  

  • 20. [Conservative treatment of pseudoparalytic myasthenia gravis].
    Vieth J
    Med Welt; 1971 Sep; 38():1496. PubMed ID: 5097679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.